EE Impact

Grindeks

Latvia · Pharma & Healthcare

LeaveRussia detail: Continue Operations

Still operating in Russia

JSC Grindeks is an internationally operating Latvian pharmaceutical company with headquarters in Riga, Latvia. Its portfolio consists of original products, generics, and active pharmaceutical ingredients. It mostly focuses on cardiovascular, central nervous system, anti-cancer and diabetes medicines.

Status last verified 03/08/2026Source checked 28/08/2023Company website ↗LeaveRussia profile ↗

Decision trail

Decision date 28/08/2023 · Reference ↗

The pharma giant Grindeks exporting to Belarus, whereas its subsidiary Kalceks exports to Russia. Grindeks' turnover in 2022 was EUR 258 million, of which EUR 70.6 in Russia.

Local stats (LeaveRussia)

Staff(RF), 2021
89
Revenue(RF), mln.USD
56
Assets(RF), mln.USD
46
Taxes(RF), mln.USD
1

Status history since 2022

  1. 03/08/2026 operating · Imported from KSE LeaveRussia

Exposure profile

Full exposure profile is a Professional feature

Energy, transport and commodity exposure, supplier/customer links in the region and sanctioned-party proximity.

Upgrade to Professional
Statuses, logos and narrative notes are compiled from public reporting and the KSE LeaveRussia project. Found an error? See our corrections policy.